Phase I Study of Erlotinib and Metformin in Triple Negative Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Nov 2016
At a glance
- Drugs Erlotinib (Primary) ; Metformin
- Indications Advanced breast cancer
- Focus Adverse reactions
- 27 Oct 2016 Planned End Date changed from 1 Sep 2016 to 1 May 2017.
- 17 Mar 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
- 10 Aug 2015 Planned End Date changed from 1 Jan 2016 to 1 Sep 2016, as reported by ClinicalTrials.gov.